Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.
about
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factorsAlcohol use in opioid agonist treatmentLow rates of hepatitis A and B vaccination in patients with chronic hepatitis C at an urban methadone maintenance program.Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programsProfiting and providing less care: comprehensive services at for-profit, nonprofit, and public opioid treatment programs in the United StatesEffect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapyHepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study.Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand.Pharmacokinetic interaction between telaprevir and methadoneIntegrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance.Bidirectional translational research: Progress in understanding addictive diseasesTreating chronic hepatitis C in recovering opiate addicts: yes, we can.The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care planProtease inhibitors for hepatitis C: economic implications.Methadone Medical Maintenance: An Early 21st-Century Perspective.Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C.Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population.Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection.Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study.A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.Analgesics in patients with hepatic impairment: pharmacology and clinical implications.
P2860
Q26853671-A41B9385-2BF1-4876-8FC4-63F90A1FA0D7Q28073797-5445687E-B6DD-4B66-9AA5-44DE68F367E3Q34315603-1D970788-9E28-4117-9518-F2FA8C90F256Q34332039-1A45F95F-269F-497A-8C0D-DDF1CF8EBCF0Q34417838-E2D59297-C087-4839-9BD9-8E5FFA9869C1Q34735072-8325E8D8-55F4-4B96-B996-4E5B4FFEDB68Q34778712-841F444A-D2C5-4A68-8980-1A8CD9E1E1D7Q34922818-AFCC0277-2F31-42CF-A097-9CB8BABFF24BQ35875495-16ED04B0-E405-46B5-89E8-F4B457D309C5Q35961748-6E39F3B4-72D8-49A1-8206-B00D54ECE370Q36021369-DC6B4686-82EA-452F-B638-1E3331200953Q36296243-860077BA-349B-4C1E-B289-A7AA793705DDQ36370353-94AF6D0C-5750-40AE-911C-36FED62D840CQ36700770-42CDAFBA-1A2E-425D-8743-53448B74DB46Q36785929-F34F1D9E-651B-49BE-835B-C950DCBA83F2Q37002923-5A9C7A82-C4E1-4A0F-BF7F-6E368547BCA8Q37251441-ED6427E9-F7F7-4DEF-95E5-560FF241D62DQ37422849-7501FD6C-17B6-4D84-88E3-FD2BA5662DF3Q37463091-FBD9D494-7E10-400D-B7B9-BA2B6F95EF04Q38120496-53965F58-568E-4527-9226-6A0496A5C28FQ38537599-4389C74D-69F5-481E-94EA-50B3A0448997Q38947375-97A7E7EA-3B41-43FC-BCDD-2D749F5829C0Q39744271-3CD758ED-2F36-431B-9BB1-D6544FF943E8Q39874376-3A50260B-0546-4D7C-9E16-A560EDD94892Q39918668-4E37955A-7AC0-47E4-AAEA-DF55E111A7EFQ40517408-ACF64B4E-1B77-48D5-8964-FF47D06B22B6Q42276687-BE50B026-2E84-489C-9BDD-3577BA28E858Q43041036-378A1F2F-7807-4BD1-8399-9243655B68BFQ44105883-8F7B3768-BD6A-4D77-9CFC-5A19C2E7C97EQ44347273-8E72287E-08F3-4C98-80E8-630D279C6E36Q52306466-F5B1ECCF-925D-4C57-8A98-195D00D1BFC5Q53689504-9D357E9C-D387-4985-91E2-E84A1B602BFA
P2860
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Critical issues in the treatme ...... ethadone maintenance patients.
@en
Critical issues in the treatme ...... ethadone maintenance patients.
@nl
type
label
Critical issues in the treatme ...... ethadone maintenance patients.
@en
Critical issues in the treatme ...... ethadone maintenance patients.
@nl
prefLabel
Critical issues in the treatme ...... ethadone maintenance patients.
@en
Critical issues in the treatme ...... ethadone maintenance patients.
@nl
P2860
P1433
P1476
Critical issues in the treatme ...... ethadone maintenance patients.
@en
P2093
David M Novick
P2860
P304
P356
10.1111/J.1360-0443.2008.02188.X
P407
P577
2008-04-16T00:00:00Z